<DOC>
	<DOCNO>NCT00306696</DOCNO>
	<brief_summary>Study examine effect different diuretic fluid retention diabetic treat rosiglitazone .</brief_summary>
	<brief_title>Examining Effect Different Diuretics Fluid Retention Diabetics Treated With Rosiglitazone .</brief_title>
	<detailed_description>A randomised , open-label , parallel group study evaluate management rosiglitazone-related fluid retention investigate effect diuretic plasma volume subject type 2 diabetes mellitus treat twelve week rosiglitazone 4mg bd addition background anti-diabetic agent .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Inclusion criterion : Subjects type 2 diabetes . Stable FPG &gt; =7.0 &lt; =12.0mmol/L . Subjects establish SU treatment SU+MET treatment least 2 month . Serum creatinine level &gt; 130 micromol/L . Exclusion criterion : Subjects take &gt; 2 concomitant oral antidiabetic agent . Subjects HbA1c &gt; =10 % . Subjects already receive diuretic medication . Subjects unstable severe angina . CHF NYHA class iiv . Subjects clinically significant hepatic disease .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>rosiglitazone</keyword>
	<keyword>fluid retention</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>diuretic</keyword>
</DOC>